SciClone Pharmaceuticals, Inc. Securities Litigation
On or around 11/20/2017 (Notice of voluntarily dismissal)
Filing Date: August 09, 2017
According to the Complaint, on June 8, 2017, SciClone announced that they had entered into a definitive agreement with affiliates of the Buyer Consortium on June 7, 2017 (“Merger Agreement”), under which Silver Biotech Investment Limited (“Parent”), an affiliate of the Buyer Consortium, through its wholly-owned subsidiary, Silver Delaware Investment Limited (“Merger Sub”), will acquire all of the outstanding shares of SciClone in an all-cash transaction (the “Proposed Transaction”).
The Complaint alleges that on August 2, 2017, Defendants issued materially incomplete and misleading disclosures in the Form PREM14A Preliminary Proxy Statement (the “Proxy”) filed with the SEC in connection with the Proposed Transaction.
This case was voluntarily dismissed on November 20, 2017.
Company & Securities Information
Defendant: SciClone Pharmaceuticals, Inc.
Industry: Major Drugs
Headquarters: United States
Ticker Symbol: SCLN
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Travis Daley, et al. v. SciClone Pharmaceuticals, Inc., et al.
COURT: N.D. California
DOCKET #: 17-CV-04563
JUDGE: Hon. Charles R. Breyer
DATE FILED: 08/09/2017
CLASS PERIOD START: 06/08/2017
CLASS PERIOD END: 08/09/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Levi & Korsinsky (San Francisco) 44 Montgomery Street, Suite 650, Levi & Korsinsky (San Francisco), CA 94104 (415) 291-2420 (415) 484-1294 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violation of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
Notice of Voluntary Dismissal without Prejudice
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available